All In Biotech

Drug Trial Radar · NCT07110363

A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer

An Open-label Phase Ib Study on the Safety, Tolerability, and Efficacy of BT02 in Treating Patients With Advanced Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Mar 2027

Study completion May 2027

Sponsor

Lead sponsor
Biotroy TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.

Conditions

  • Advanced Malignant Solid Tumor
  • Advanced Lung Cancer
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

Interventions

  • BT02Drug

    monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: through study completion, an average of 2 years
  2. Dose limited toxicity incidenceTime frame: Through the dose escalation phase , an average of 8 months
  3. Maximum tolerated dose(MTD)Time frame: Through the dose escalation phase, an average of 8 months
  4. Recommended Phase II dose (RP2D)Time frame: Through study completion, an average of 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.